Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
Journal
JTO clinical and research reports
Journal Volume
3
Journal Issue
10
Date Issued
2022-10
Author(s)
Wu, Yi-Long
Lu, Shun
Zhou, Jianying
Seto, Takashi
Ahn, Myung-Ju
Su, Wu-Chou
Yamamoto, Noboru
Kim, Dong-Wan
Paolini, Jolanda
Usari, Tiziana
Iadeluca, Laura
Wilner, Keith D
Goto, Koichi
Abstract
Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present the final OS, quality of life (QoL), and safety data after an additional 3 years of follow-up.
Subjects
Asia; Crizotinib; NSCLC; Phase 2; ROS1
SDGs
Type
journal article